Olema Oncology is a clinical-stage biopharmaceutical company focused on discovery, development and commercialization of targeted therapies for women’s cancers. Its lead product candidate, OP-1250, is described as a complete estrogen receptor antagonist (CERAN) and a selective ER degrader (SERD). OP-1250 is being evaluated in a Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive, HER2-negative breast cancer whose disease has progressed on endocrine therapy. The company plans to use the financing to advance clinical development of OP-1250 and to expand ongoing research and development activities. Olema also plans additional studies evaluating OP-1250 in combination with other targeted breast cancer therapies. The company is led by President & CEO Sean P. Bohen, M.D., Ph.D., and CFO/COO Shane Kovacs. Olema Oncology is a San Francisco-based biopharmaceutical company focused on developing innovative targeted therapies for women's cancers. Its lead program, OP-1250, is a potential best-in-class complete estrogen receptor antagonist (CERAN) in development for ER-positive, HER2-negative breast cancer. The company intends to use the new financing to advance OP-1250 into Phase 1/2 clinical development and to expand ongoing research and development activities. Olema expected to initiate a Phase 1/2 dose-escalation and expansion trial in the second half of 2020. The trial will evaluate OP-1250 as a single agent in women with ER+, HER2- recurrent, locally advanced or metastatic breast cancer, followed by studies of OP-1250 in combination with other targeted breast cancer therapies.

Total raised

$139M

Funding rounds

2

Latest round

Series C

Latest activity

Oct 2020